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METHODS OF USING BLACK BEAR 
PARATHYROID HORMONE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application No. 60/736,145, filed Nov. 10, 2005, which is 
incorporated herein by reference in its entirety. 
STATEMENT REGARDING 
FEDERALLY-SPONSORED RESEARCH 
This invention was made with United States government 
support awarded by the National Institutes of Health (NIAMS 
AR050420 and NIA R21AA 14399-01A2) and the National 
Science Foundation (IBN-0343515). The United States gov-
ernment has certain rights in this invention. 
BACKGROUND 
Bone loss diseases are currently a health threat for approxi-
mately 44 million Americans, including 10 million with 
osteoporosis and 34 million with low bone mass and at risk 
for developing osteoporosis. The number of Americans with 
osteoporosis is expected to rise by 2020. Consequently, a 
large number ofindividuals are at risk for bone fracture due to 
low bone mass. Approximately 40% of white women and 
13% of white men over age 50 are at risk for hip, spine, or 
forearm fracture within their lifetime. The costs associated 
with osteoporosis-related fractures were approximately $18 
billion dollars in 2002, and are expected to continue climbing. 
2 
a polypeptide comprising amino acid residues 1-34 of SEQ 
ID NO: 2, wherein contacting the bone-forming cell with the 
polypeptide decreases the ratio of expression levels of Bax 
protein to Bcl-2 protein in the bone-forming cell. 
In yet another embodiment, the invention provides a 
method of increasing the expression level of a bone matrix 
protein, a transcriptional activator, or a transcriptional regu-
lator in a bone-forming cell comprising contacting the bone-
forming cell with an effective amount of a polypeptide com-
IO prising amino acid residues 1-34 of SEQ ID NO: 2, wherein 
contacting the bone-forming cell with the polypeptide 
increases the expression level of the bone matrix protein, the 
transcriptional activator, or the transcriptional regulator in the 
15 bone-forming cell. 
In still another embodiment, the invention provides a 
method of enhancing bone mineral density, increasing bone 
mass, decreasing bone loss, or reducing the incidence of bone 
fractures in a subject, comprising contacting a bone-forming 
20 cell in the subject with an effective amount of a polypeptide 
comprising amino acid residues 1-34 of SEQ ID NO: 2, 
wherein contacting the bone-forming cell with the polypep-
tide enhances bone mineral density, increases bone mass, 
decreases bone loss, or reduces the incidence of bone frac-
25 tures in the subject. 
In yet another embodiment, the invention provides a 
method of enhancing bone mineral density, increasing bone 
mass, decreasing bone loss, or reducing the incidence of bone 
fractures, or any combination thereof, in a subject, compris-
30 ing contacting a bone-forming cell in the subject with an 
effective amount of a polypeptide comprising bear parathy-
roid hormone or a functional fragment thereof, wherein con-
tacting the bone-forming cell with the polypeptide enhances In addition to primary (age-related) osteoporosis, disuse 
osteoporosis is an important clinical problem, especially for 
patients chronically immobilized due to stroke or spinal cord 
injury. Fracture rates double compared to healthy controls in 
the first year following spinal cord injury and are also elevated 
compared to healthy controls after the onset of stroke. Disuse 
increases fracture rates primarily because reduced skeletal 
loading causes unbalanced bone remodeling which leads to 40 
bone loss. 
35 bone mineral density, increases bone mass, decreases bone 
loss, or reduces the incidence of bone fractures in the subject. 
In still another embodiment, the invention provides an 
isolated polypeptide consisting essentially of amino acid resi-
dues 1-34 of SEQ ID NO: 2. 
In yet another embodiment, the invention provides an iso-
lated polypeptide consisting essentially of amino acid resi-
dues 1-36 of SEQ ID NO: 2. 
SUMMARY 
In one embodiment, the invention provides an isolated 45 
polypeptide comprising at least 10 consecutive amino acid 
residues of SEQ ID NO: 2 wherein the polypeptide comprises 
at least one of amino acid residues 41 and 52 of SEQ ID NO: 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows ultimate stress, a measure of bone strength, 
and ash fraction, a measure of bone mineral content, which 
both increase with age in black bears. 
2. The present invention also provides an isolated polynucle-
otide comprising SEQ ID NO: 1. 
In another embodiment, the invention provides a method of 
increasing cAMP levels in a bone-forming cell comprising 
contacting the bone-forming cell with an effective amount of 
FIG. 2 shows that serum osteocalcin levels are positively 
50 correlated with serum parathyroid hormone (PTH) levels 
(p=0.0007, n=27) in black bears for pooled pre-hibernation, 
hibernation, and post-hibernation samples. 
a polypeptide comprising amino acid residues 1-34 of SEQ 
ID NO: 2, wherein contacting the bone-forming cell with the 55 
polypeptide increases cAMP levels in the bone-forming cell. 
In yet another embodiment, the invention provides a 
method of reducing apoptosis in a bone-forming cell com-
prising contacting the bone-forming cell with an effective 
amount of a polypeptide comprising amino acid residues 1-34 60 
of SEQ ID NO: 2, wherein contacting the bone-forming cell 
with the polypeptide reduces apoptosis in the bone-forming 
cell. 
FIG. 3 shows normalized serum resorption (ICTP) and 
formation (PICP and osteocalcin) marker concentrations dur-
ing the 3 month disuse period. 
FIG. 4 shows that the amount of PGE2 released by osteo-
blastic cells was greatest when the cells were treated with 
serum collected in the post-hibernation period. 
FIG. 5 shows the sequence of the mature black bear PTH 
protein (SEQ ID NO: 2) compared to other known PTH 
sequences, including monkey (SEQ ID NO: 5), human (SEQ 
ID NO: 6), horse (SEQ ID NO: 7), dog (SEQ ID NO: 8), cat 
(SEQ ID NO: 9), bovine (SEQ ID NO: 10), pig (SEQ ID NO: In still another embodiment, the invention provides a 
method of decreasing the ratio of expression levels of Bax 
protein to Bcl-2 protein in a bone-forming cell comprising 
contacting the bone-forming cell with an effective amount of 
65 11), rat (SEQ ID NO: 12), and mouse (SEQ ID NO: 13). 
FIG. 6 shows that both human and black bear PTH 1-34 
upregulate osteocalcin (n=2). 
US 7,994,129 B2 
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FIG. 7 shows the effects of human and black bear PTH 1-34 
on apoptosis-related gene expression (n=4). 
DETAILED DESCRIPTION 
In humans and most other mammals, factors such as aging 
and extended periods of disuse can lead to osteoporosis and 
4 
during hibernation, 1t 1s likely that most of the calcium 
released from bone by resorption is recycled back into bone 
via osteoblastic bone formation. Ionized calcium is found to 
increase by about 23% during hibernation, possibly because 
5 of the lag time between resorption and formation. Paradoxi-
cally, black bear PTH levels are highest when levels of ion-
ized calcium are highest (Table 1). Taken together, these 
findings suggest that bears have evolved biological mecha-an increased risk of fracture. Disuse due to spinal cord lesion 
significantly decreases bone mineral density, particularly in 
the tibia and femur, and significantly reduces the cross-sec- 10 
tional moment ofinertia of the femoral diaphysis. Thus, bone 
bending strength is reduced by spinal cord injury and fracture 
risk is increased. Disuse due to stroke also increases fracture 
nisms to avoid osteoporosis. 
The mechanisms that uncouple bone formation from 
resorption during disuse in most animals are unknown, but 
likely involve both mechanical and biochemical factors. Lack 
of mechanical strain may lead to increased resorption by 
initiating osteocyte apoptosis and concomitantly reducing 
osteoblastic activity. Hormones such as human PTH can sen-
sitize bone cells to mechanical stimulation and synergisti-
risk. In addition, mechanical unloading of bone can cause 
rapid bone loss due to immediate increases in bone resorption 15 
in addition to sustained decreases in bone formation. Disuse-
induced changes in bone remodeling increase intracortical 
porosity, and reduce the cross-sectional and mechanical prop-
erties of long bone diaphyses. Unloading also considerably 
reduces trabecular bone mass and microarchitecture. 
The deleterious effects of disuse on bone may continue into 
the remobilization period. Some bone may be recovered dur-
ing remobilization, but recovery is slow and often incom-
plete. For example, the rate of bone loss during bedrest is 
more than three times greater than the rate of bone gain during 
remobilization, and the recovery of bone lost in spaceflight 
can be incomplete even after 5 years. When disuse-induced 
changes in bone can be completely reversed by resumed 
activity, the remobilization period is often 2 to 3 times longer 
than the immobilization period. Bone formation decreases 
and/or bone resorption increases in many situations that 
reduce mechanical loads on bone. However, both resorption 
and formation increase during canine forelimb immobiliza-
tion, yet there is significant bone loss in that case. Likewise, 
thigh bone turnover occurs in patients with spinal cord injury, 
which leads to bone loss and increased fracture incidence. 
In contrast to this, black bears do not suffer significant bone 
loss due either to aging (FIG. 1) or, more importantly, to the 
extended periods of disuse that occur during hibernation. 
Hibernating black bears have immobilization and active peri-
ods that can be approximately equal in length in northern 
regions. Data on serum markers of bone metabolism (see 
below) suggest that both resorption and formation increase 
during disuse in bears, with a normal lag time (i.e., reversal 
period) between resorption and formation, and that the 
increase in formation remains coupled and balanced with the 
increase in resorption. Histological data from black bear iliac 
crest biopsies also show increased resorption and formation 
during inactivity. However, bears are unique in that trabecular 
bone volume, bone mineral density, and bone mineral content 
do not decrease during hibernation. Moreover, cortical bone 
strength and ash fraction increase with age, and porosity does 
not change with age in black bears, despite annual periods of 
disuse. Cortical bone porosity is significantly lower in hiber-
nating grizzly bears than in active grizzly bears, and femoral 
cross-sectional geometry and strength are unaffected by 
hibernation. 
Bears have evolved many unique biological mechanisms to 
survive long periods of immobilization without food. These 
mechanisms appear to include the recycling of calcium and 
other products of bone catabolism, since bears increase bone 
turnover but do not excrete waste during hibernation. In 
humans, bedrest-induced disuse osteoporosis is caused pri-
marily by increased resorption without a corresponding 
increase in formation. This results in hypercalcemia and a 
negative calcium balance brought about by increased urinary 
and fecal calcium. Since bears do not urinate or defecate 
cally, with mechanical loading, increase bone formation. 
Human PTH given once daily to humans increases bone mass 
and decreases fracture incidence. Thus, in black bears, circu-
20 lating PTH may sensitize bone cells to low levels of mechani-
cal stimulation (possibly due to shivering or repositioning in 
the hibernaculum) to help maintain bone formation during 
disuse. PTH may also help maintain bone formation in black 
bears by stimulating osteoblast differentiation and inhibiting 
25 osteoblast apoptosis. 
PTH is the primary regulator of blood calcium levels, and 
thus plays a role in maintaining homeostatic serum calcium 
levels in black bears during disuse. Serum PTH levels are 
positively correlated with the bone formation marker osteo-
30 calcin in active and hibernating black bears (FIG. 2), and both 
osteocalcin and PTH increase during hibernation. In addition, 
black bear PTH concentration is highest when ionized cal-
cium concentration is highest. Since bone resorption 
increases during hibernation but total serum calcium (tCa) 
35 remains unchanged, increased levels of PTH likely cause 
increased renal reabsorption of calcium, facilitating the recy-
cling of mineral back into the bone with a balanced increase 
in bone formation. This leads to the observed preservation of 
trabecular and cortical bone properties like bone mineral 
40 density ("BMD") and cortical porosity. Bone resorption 
increases during hibernation, but blood calcium concentra-
tion remains constant despite the fact that bears do not excrete 
waste during hibernation. The calcium liberated by bone 
resorption during hibernation may be recycled and put back 
45 into bone by maintaining balanced coupling of bone forma-
tion with bone resorption. This supports the idea that PTH has 
anabolic effects in hibernating black bears and provides an 
explanation for the bears' distinctive ability to maintain bal-
anced bone remodeling during hibernation. The anabolic 
50 effects of PTH may be enhanced in black bears when physical 
activity is resumed following arousal from hibernation. 
Mechanical loading and human PTH have previously been 
shown to act synergistically to increase bone formation in 
vivo in rats and biochemical signaling in vitro. During remo-
55 bilization in the spring, bone formation in the black bear, as 
indicated by serum osteocalcin, remains higher than pre-
hibernation levels. 
The sequence for the polynucleotide which encodes black 
bear (Ursus americanus) parathyroid hormone (PTH) (SEQ 
60 ID NO: 1) was discovered as well as the polypeptide sequence 
for the mature 84 amino acid PTH protein (SEQ ID NO: 2). In 
addition, the cDNA (SEQ ID NO: 3) which encodes the full 
length PTH protein (SEQ ID NO: 4), including a 25 amino 
acid signal peptide (amino acid residues 1-25 of SEQ ID NO: 
65 4) and a 6 amino acid propeptide (amino acid residues 26-31 
of SEQ ID NO: 4) has been sequenced. The mature black bear 
PTH protein differs from other known PTH proteins (FIG. 5). 
US 7,994,129 B2 
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Compared to human PTH, black bear PTH has 11 different 
amino acid residues out of a total of the 84 amino acid resi-
dues of the full-length, mature PTH polypeptide. Also 
described herein are various methods of use for black bear 
PTH and functional fragments thereof. It is specifically envi-
sioned that polypeptide subfragments comprising at least 10 
consecutive amino acid residues of SEQ ID NO: 2 and includ-
ing at least one of amino acid residues 41 or 52 can be used to 
develop antibodies specific for black bear PTH. These anti-
bodies can be used to quantify black bear PTH, e.g. in an 
ELISA assay. 
PTH receptors on the surface of bone-forming cells are 
coupled to cyclic adenosine monophosphate ( cAMP)-depen-
dent second-messenger signaling pathways inside the cells. 
These signaling pathways, in turn, lead to increased expres-
sion of genes involved in bone formation such as those encod-
ing type I collagen, osteonectin, and osteopontin. Since the 
cAMP/protein kinase A pathway is responsible for the major-
ity of PTH-induced increases in histological and serum indi-
ces of bone formation, it follows that an increased cAMP 
response can lead to greater bone formation. A relatively 
small number of amino acid substitutions in the sequence of 
a given PTH protein can stimulate greater cyclic adenosine 
monophosphate ( cAMP) production compared to the native 
form. For example, ovariectomized rats demonstrated a 25% 
greater bone formation response to daily 25 µg injections of 
bovine PTH 1-34 than to rat PTH 1-34, where rat PTH 1-34 
has 5 amino acid sequence differences compared to bovine 
PTH 1-34. Injection of bovine PTH 1-34 results in a 37% 
greater increase in bone volume fraction during treatment. 
Thus, it is likely that the amino acid substitutions in black 
bear PTH cause it to induce greater cAMP production in 
bone-forming cells than human PTH. PTH, in general, elicits 
a greater bone formation response by mechanisms such as 
decreasing osteoblast apoptosis, increasing osteoblast differ-
entiation via Runx2, downregulating SOST-based negative 
feedback in osteocytes, and increasing production of mRNA 
for bone matrix proteins, all via cAMP-mediated pathways. 
Although it is not necessary to understand the mechanism of 
an invention, it is believed that black bear PTH is likely more 
osteogenic than other forms of PTH, which explains why 
black bears are uniquely able to maintain balanced bone 
remodeling during disuse. In another embodiment of the 
present invention, contacting a bone-forming cell with black 
bear PTH or a functional fragment thereof increases cAMP 
levels in the bone-forming cell. In another embodiment of the 
present invention, the bone-forming cell is contacted with a 
polypeptide comprising amino acid residues 1-34 or 1-36 of 
SEQ ID NO: 2. In another embodiment of the present inven-
tion, the bone-forming cell is contacted with a polypeptide 
comprising SEQ ID NO: 2. In another embodiment, the bone-
forming cell is contacted with a polypeptide comprising 
amino acid residues 11-84 or 7-84 of SEQ ID NO: 2. 
As used herein, "contacting a cell" with a PTH polypeptide 
includes adding the polypeptide to the culture solution, in the 
case of in vitro experiments, or administering the polypeptide 
to a subject using appropriate administration procedures for 
polypeptide therapeutic agents. "Contacting a cell" also 
includes introducing into a subject an exogenous polynucle-
otide that encodes the desired polypeptide in an expression 
system so as to synthesize and release the polypeptide in the 
subject. As used herein, "bone-forming cells" includes, but is 
not limited to, osteoblasts, osteocytes, bone lining cells, 
chondroblasts, and chondrocytes. Suitably, the bone-forming 
cell may be in a subject. 
Bone-forming cells regularly tum over, with most of the 
cells' death being due to programmed cell death, or apoptosis. 
6 
Given this regular rate of turnover, any mechanism that 
decreases apoptosis of bone-forming cells will lead to an 
increased number of bone-forming cells which presumably 
will promote bone growth. Thus, in another embodiment of 
5 the present invention, contacting a bone-forming cell with 
black bear PTH or a functional fragment thereof reduces 
apoptosis in the bone-forming cell. In another embodiment of 
the present invention, the bone-forming cell is contacted with 
a polypeptide comprising amino acid residues 1-34 or 1-36 of 
10 SEQ ID NO: 2. In another embodiment of the present inven-
tion, the bone-forming cell is contacted with a polypeptide 
comprising SEQ ID NO: 2. 
Moreover, it is possible that several of the larger C-terminal 
fragments of endogenous black bear PTH play a role in sea-
15 sonal bone remodeling processes via binding to CPTHRs 
(C-terminal PTH receptors). Specifically, C-terminal frag-
ments of bear PTH may antagonize the calcemic effects of 
PTH 1-84 and 1-34 by preventing osteoclastogenesis and 
possibly by affecting mature osteoclast activity that would 
20 normally occur in response to resorptive stimuli such as dis-
use (Divieti, P. et al., 2002, Endocrinology 143(1): 171-6). 
This may help bears to maintain homeostatic calcium levels 
throughout hibernation. Thus, in another embodiment of the 
present invention, osteocytes and osteoblasts may be con-
25 tacted with a polypeptide comprising amino acid residues 
11-84 or 7-84 of SEQ ID NO: 2. 
The protein Bax promotes apoptosis while the Bcl-2 pro-
tein protects cells from apoptosis, and a decrease in the 
expression ratio of Bax to Bcl-2 is indicative of a decrease in 
30 apoptosis in the particular cell population. Thus, in another 
embodiment of the present invention, contacting a bone-
forming cell with black bear PTH or a functional fragment 
thereof decreases the ratio of expression levels of Bax protein 
relative to expression levels of Bcl-2 protein in the bone-
35 forming cell. In another embodiment of the present invention, 
the bone-forming cell is contacted with a polypeptide com-
prising amino acid residues 1-34 or 1-36 of SEQ ID NO: 2. In 
another embodiment of the present invention, the bone-form-
ing cell is contacted with a polypeptide comprising SEQ ID 
40 NO: 2. In another embodiment of the present invention, the 
bone-forming cell is contacted with a polypeptide comprising 
amino acid residues 11-84 or 7-84 of SEQ ID NO: 2. 
Example 11 shows that black bear PTH 1-34 decreases the 
expression ratio of Bax/Bcl-2 in cultured cells whereas 
45 human PTH 1-34 increases the expression ratio ofBax/Bcl-2 
(FIG. 7). Thus, black bear PTH 1-34 appears to be more 
effective at preventing apoptosis than human PTH 1-34. 
Without being bound by theory, this difference may be the 
result of the two amino acid differences between human and 
50 black bear PTH 1-34. These data suggest that bear PTH is 
more anabolic than human PTH, since decreased osteoblast 
apoptosis may contribute to the bone formation response 
induced by PTH treatment. 
Contacting a bone-forming cell with black bear PTH or a 
55 functional fragment thereof also increases the expression 
level of bone matrix protein, a transcriptional activator, or a 
transcriptional regulator in the bone-forming cell. In another 
embodiment of the present invention, the transcriptional acti-
vator is Runx2. In another embodiment of the present inven-
60 tion, the transcriptional regulator is c-fos. Bone matrix pro-
teins may suitably include osteocalcin, osteopontin, and type 
I collagen. In another embodiment of the present invention, 
the bone-forming cell is contacted with a polypeptide com-
prising amino acid residues 1-34 or 1-36 of SEQ ID NO: 2. In 
65 another embodiment of the present invention, the bone-form-
ing cell is contacted with a polypeptide comprising SEQ ID 
NO: 2. In another embodiment of the present invention, the 
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bone-forming cell is contacted with a polypeptide comprising 
amino acid residues 11-84 or 7-84 of SEQ ID NO: 2. 
Exogenous human PTH is used to treat post-menopausal 
and age-related osteoporosis in humans, but it is not an ideal 
therapeutic. Only recombinant human PTH 1-34 (LY333334, 5 
Eli Lilly, Indianapolis Ind.) is currently approved for clinical 
use, and only one form of recombinant human PTH 1-84 is 
under consideration for approval by the U.S. Food and Drug 
Administration (ALXl-11, NPS Pharmaceuticals, Parsip-
pany, N.J.). Though LY333334 and ALXl-11 can stimulate 10 
approximately the same magnitude ofbone formation in vivo, 
their biological actions are not identical. For example, PTH 
1-34 down-regulates production of procollagen-1 mRNA, 
whereas PTH 1-84 does not (Nasu et al., 1998, Endocr J, 45, 
229-34). In addition, it has also been determined that the 15 
C-terminal portion of human PTH, when cleaved from the 
mature hormone, has important biological functions such as 
inhibition of bone resorption. 
Long-term usage of either LY333334 or ALXl-11 gener-
ates osteosarcoma in rats, but preliminary results indicate that 20 
human PTH 1-84 has a lower rate of carcinogenicity than 
human PTH 1-34, possibly because C-terminal fragments of 
exogenous human PTH 1-84 (arising from peripheral pro-
teolytic processing) can bind to C-terminal PTH receptors 
(CPTHRs) and increase osteocyte apoptosis. Thus, though 25 
equally anabolic, human PTH 1-84 may be a superior 
osteoporosis therapy compared to human PTH 1-34. How-
ever, human PTH 1-84 cannot completely restore lost bone; it 
has been suggested that men and women can lose between 
20-30% of cortical and cancellous bone due to age-related 30 
osteoporosis, but only 8% is recovered using ALXl-11 dur-
ing its suggested treatment regimen. Therefore, there exists a 
clinical need for osteoporosis treatments with greater osteo-
genic capabilities. 
In an additional embodiment of the present invention, con- 35 
tacting a bone-forming cell in a subject with black bear PTH 
or a functional fragment thereof increases bone mineral den-
sity, increases bone mass, decreases bone loss or reduces the 
incidence of bone fracture in the subject. In another embodi-
ment of the present invention, the bone-forming cell is con- 40 
tacted with a polypeptide comprising amino acid residues 
1-34 or 1-36 of SEQ ID NO: 2. In another embodiment of the 
present invention, the bone-forming cell is contacted with a 
polypeptide comprising SEQ ID NO: 2. In another embodi-
ment of the present invention, the bone-forming cell is con- 45 
tacted with a polypeptide comprising amino acid residues 
11-84 or 7-84 of SEQ ID NO: 2. 
Suitably, contacting a bone-forming cell in a subject with 
black bear PTH or a functional fragment thereof increases 
bone mineral density, increases bone mass, decreases bone 50 
loss or reduces the incidence of bone fracture by at least about 
5% or at least about 10%. The increase in bone mineral 
density, increase in bone mass, decrease in bone loss or reduc-
tion in the incidence of bone fracture may be at least about 
15%, at least about 30%, at least about 50%, at least about 55 
75% or at least about 90%. The increase in bone mineral 
8 
develop osteoporosis. Risk factors for developing osteoporo-
sis include: personal history of fracture after age 50; current 
low bone mass; history of fracture in a first-degree relative; 
being female; being thin and/or having a small frame; 
advanced age; a family history of osteoporosis; estrogen defi-
ciency as a result of menopause, especially early or surgically 
induced; abnormal absence of menstrual periods (amenor-
rhea); anorexia nervosa; low lifetime calcium intake; vitamin 
D deficiency; use of certain medications ( corticosteroids, 
chemotherapy, anticonvulsants and others); presence of cer-
tain chronic medical conditions, such as those that decrease 
calcium absorption in the gut such as Crohn's disease; low 
testosterone levels in men; an inactive lifestyle; current ciga-
rette smoking; excessive use of alcohol; and being Caucasian 
or Asian; although African Americans and Hispanic Ameri-
cans are at significant risk as well. Moreover, women can lose 
up to 20 percent of their bone mass in the five to seven years 
following menopause, making them more susceptible to 
osteoporosis. 
Black bear PTH or functional fragments thereof are also 
useful as a preventative (rather than a restorative), or prophy-
lactic, measure to combat disuse osteoporosis or to prevent 
osteoporosis in a subject at risk for developing osteoporosis. 
Since bears appear to be the only animals that maintain bal-
anced bone remodeling during disuse, black bear PTH or 
functional fragments thereof are also useful to prevent bone 
loss during reduced skeletal unloading that occurs, for 
example, in astronauts during spaceflight and in spinal cord 
injury patients after injury. 
Black bear PTH or functional fragments thereof may be 
administered in combination with calcium and/or vitamin D. 
The calcium and/or vitamin D may be administered concur-
rently with black bear PTH or functional fragment thereof or 
may be administered before or after black bear PTH or func-
tional fragments thereof. Suitably, "Vitamin D" refers to the 
entire Vitamin D class of compounds. 
Administration of black bear PTH or functional fragments 
thereof or compositions comprising black bear PTH or func-
tional fragments thereof can be accomplished by any suitable 
technique. Black bear PTH or functional fragment thereof 
may be administered by any suitable route including, for 
example, oral, nasal, rectal, and parenteral routes of admin-
istration. As used herein, the term parenteral includes but is 
not limited to subcutaneous, intradermal, intravenous, intra-
muscular, intraperitoneal, and intrathecal administration, 
such as by injection. As is discussed above, administration of 
a polypeptide includes administration of an exogenous poly-
nucleotide operably connected to a promoter such that the 
polynucleotide expresses the polypeptide in the subject. 
Administration of the polypeptide also includes administra-
tion of a viral vector comprising a polynucleotide encoding 
the polypeptide. Suitably, the viral vector is an adenoviral 
vector. 
Black bear PTH or functional fragments thereof, or com-
positions comprising black bear PTH or functional fragments 
thereof, can be administered continuously or at discrete time 
intervals as can be readily determined by a person skilled in 
the art. An ordinarily skilled clinician can determine a suit-
able amount of black bear PTH or a functional fragment 
density, increase in bone mass, decrease in bone loss or reduc-
tion in the incidence of bone fracture is determined by mea-
suring the desired characteristic on the same patient before 
and after treatment by a technique known to one of ordinary 
skill in the art. For example, bone mineral density can be 
determined by methods involving taking dual energy x-rays 
(DEXA) or CT scans ofbones in the spinal colurmi, wrist, arm 
or leg. 
60 thereof to be administered to a subject. 
The subject may suitably be a mammal, including without 
limitation human, horse, dog, cat, mouse, bear, bovine, pig, or 
deer. The subject may have osteoporosis or may be at risk to 
The specific effective dose for any particular subject will 
depend upon a variety of factors, including the disorder being 
treated and the severity of the disorder; activity of the specific 
compound employed; the specific composition employed; the 
65 age, body weight, general health, sex and diet of the subject; 
route of administration; the rate of excretion or inactivation of 
black bear PTH or functional fragments thereof employed; 
US 7,994,129 B2 
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As used herein, an "isolated" nucleic acid molecule, poly-
nucleotide, polypeptide, or the like, as the case may be, refers 
to a component that is at least partially purified from contami-
nants ( e.g., other species of polynucleotides, polypeptides, or 
the duration of the treatment; other pharmaceuticals used in 
combination or coincidental with black bear PTH or func-
tional fragments thereof and like factors well known in the 
medical arts. For example, it is well within the level of ordi-
nary skill in the art to start doses at levels lower than those 
required to achieve the desired effect and to gradually 
increase the dosage until the desired effect is achieved. 
Suitably, the dosage of black bear PTH or functional frag-
ments thereof in one embodiment is in a range of 0.10 µg/kg 
per day to 40 µg/kg per day. In another embodiment, the 
dosage is in a range of 5 µg/kg per day to 20 µg/kg per day. In 
still another embodiment, the dosage is 10 µg/kg per day. In 
another embodiment, the dosage is in a range of 10 µg/day to 
400 µg/day per subject. In yet another embodiment, the dos-
age is in a range of20 µg/day to 40 µg/day per subject. In still 
another embodiment, the dosage is 30 µg/day per subject. In 
one embodiment the subject is a human. Suitably, the daily 
dosages in one embodiment are given for one week, in 
another embodiment for one month, in yet another embodi-
ment for three months, in yet another embodiment for six 
months, in still another embodiment for one year, in yet 
another embodiment for one and a half years, in still another 
embodiment for two years, and in yet another embodiment for 
three years. 
5 the like) that is found other than in its natural state. An isolated 
nucleic acid, polynucleotide, or polypeptide may contain less 
than about 50%, suitably less than about 75%, and most 
suitably less than about 90%, of the cellular components with 
which it was originally associated. A polynucleotide ampli-
10 fled using PCR so that it is sufficiently and easily distinguish-
able ( on a gel, for example) from the rest of the cellular 
components is considered "isolated". The nucleic acid mol-
ecules, polynucleotides, and polypeptides of the invention 
may be "substantially pure," i.e., having the highest degree of 
15 purity that can be achieved using purification techniques known in the art. 
As used herein, a "functional fragment" refers to any 
region or portion of a polypeptide or polynucleotide which is 
a region or portion of a larger polypeptide or polynucleotide, 
the region or portion having an activity or function attribut-
20 able to the larger polypeptide orpolynucleotide. For example, 
a functional fragment of human PTH is the 1-34 region of 
humanPTH. 
If desired, the effective daily dose may be divided into 25 
multiple doses for purposes of administration. Consequently, 
single dose compositions may contain such amounts or sub-
multiples thereof to make up the daily dose. If desired, a 
suitable delivery device is loaded with the effective daily dose 
for more than one day, for example, for seven days, fourteen 30 
days, twenty-one days, twenty-eight days or the like, and the 
delivery device is used to repeatedly administer the desired 
daily single dose or daily multiple doses for the desired total 
numberof days. As noted, those ofordinary skill in the art will 
readily optimize effective doses and co-administration regi- 35 
mens as determined by good medical practice and the clinical 
condition of the individual subject. 
Compositions containing black bear PTH or functional 
fragments thereof useful in the methods of the present inven-
tion can be formulated according to known methods for pre-
paring pharmaceutically useful compositions. Formulations 40 
are described in detail in a number of sources which are well 
known and readily available to those skilled in the art. For 
example, Remington's Pharmaceutical Science, by E. W. 
Martin, describes formulations which can be used in the 
disclosed methods. In general, the compositions will be for- 45 
mulated such that an effective amount of the polypeptide is 
combined with a suitable carrier in order to facilitate effective 
administration of the composition. 
The compositions used in the present methods can also be 
in a variety of forms. These include, for example, solid, semi- 50 
solid, and liquid dosage forms, such as tablets, pills, powders, 
liquid solutions or suspension, suppositories, injectable and 
infusible solutions, and sprays. The form will depend on the 
intended mode of administration and therapeutic application. 
The compositions also suitably include conventional pharma- 55 
ceutically acceptable excipients which are known to those 
skilled in the art. Examples of excipients include water for 
injection, ethanol, dimethyl sulfoxide, glycerol, alumina, 
starch, glacial acetic acid, sodium acetate, mannitol, meta-
cresol, hydrochloric acid and/or sodium hydroxide to adjust 
the pH of a composition to a suitable value, and equivalent or 60 
otherwise suitable carriers and diluents. To provide for the 
administration of such dosages for the desired application, 
pharmaceutical compositions will comprise between about 
0.1% and 99%, and suitably between about 1 and 15% by 
weight of the total of one or more of the polypeptides of the 65 
present invention based on the weight of the total composition 
including the carrier or diluent. 
As used in this specification and the appended claims, the 
singular forms "a," "an," and "the" include plural referents 
unless the content clearly dictates otherwise. It should also be 
noted that the term "or" is generally employed in its sense 
including "and/or" unless the content clearly dictates other-
wise. All publications, patents and patent applications are 
herein expressly incorporated by reference in their entirety 
for all purposes to the same extent as if each individual 
publication or patent application was specifically and indi-
vidually incorporated by reference. In case of conflict 
between the present disclosure and the incorporated patents, 
publications and references, the present disclosure should 
control. 
It also is specifically understood that any numerical range 
recited herein includes all values from the lower value to the 
upper value, i.e., all possible combinations of numerical val-
ues between the lowest value and the highest value enumer-
ated are to be considered to be expressly stated in this appli-
cation. For example, if a concentration range is stated as 1 % 
to 50%, it is intended that values such as 2% to 40%, 10% to 
30%, or 1 % to 3%, etc., are expressly enumerated in this 
specification. If a concentration range is "at least 5%," it is 
intended that all percentage values up to and including 100% 
are also expressly enumerated. These are only examples of 
what is specifically intended. 
The following Examples are provided to assist in a further 
understanding of the invention. The particular materials, 
methods and conditions employed are intended to be illustra-
tive of the invention and are not limiting upon the scope of the 
invention. 
Example 1 
Sequencing of Black Bear PTH 1-84 
Genomic DNA Extraction 
Blood was collected from a captive female black bear and 
stored at 4° C. Genomic DNA was extracted from the whole 
blood samples within 2 weeks, using the Genomic Prep Blood 
DNA Isolation Kit (Amersham Biosciences, Piscataway, 
N.J.) according to the manufacturer's instructions. 
PCR Cloning and Sequencing 
Black bear genomic DNA was used for PCR amplification 
of PTH, using consensus primers designed based on align-
ment of eight full-length mammalian PTH sequences avail-
able in GenBank including bovine (Bos faun.ts, AAA30749), 
cat (Pelis catus, Q9GL67), dog (Canisfamiliaris, P52212), 
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human (Homo sapiens, NP _000306), macaque (Macacafas-
cicularis, Q9XT35), mouse (Mus musculus, NP _065648), 
pig (Sus scrofa, NP _999566), and rat (Rattus norvegicus, 
NP _0587 40). PCR amplification was performed using 10-15 
ng genomic DNA, 100 µM dNTPs, 0.2 µMeach primer, and 5 
1 unit REDTaq (Sigma, St. Louis, Mo.) in 20 µL reaction 
volume. PCR products were gel-purified using the Ultra Clean 
GelSpin Kit (MoBio Carlsbad, Calif.) and cloned into the 
pCRII vector using the TA cloning kit (Invitrogen, Carlsbad, 
Calif.). DNA sequencing was performed using the DTCS 10 
Quick Start kit and the CEQ8000 Genetic Analysis System 
(Beckman Coulter, Fullerton, Calif.), following the manufac-
turer's instructions. 
Sequence Analysis 
Nucleotide sequences were searched against the GenBank 15 
protein database using BlastX (Altschul et al., 1997; Nucleic 
Acids Res., 25, 3389-402) to confirm their putative identity as 
PTH. Multiple sequence alignment was performed by Clust-
alW version 1.82 (Chenna et al., 2003; Nucleic Acids Res., 
31, 3497-500). Phylogenetic analysis was carried out using 20 
the neighbor-joining (NJ) method implemented in the 
Molecular Evolutionary Genetics Analysis (MEGA) package 
version 3.0 (Kumar et al., 2004; BriefBioinform., 5, 150-63), 
with the pairwise deletion option for handling alignment 
gaps, and with the Poisson correction model for distance 25 
computation. 
PTH Cloning and Sequence Analysis 
12 
samples were collected from each bear every 10 days from the 
first of October through the end of May. Hibernation began in 
early January and ended in early April. Thus, the collection 
dates encompassed an active pre-hibernation period, a disuse 
hibernation period, and an active post-hibernation remobili-
zation period. 
Black Bear Osteocalcin Purification and RIA Procedures 
Black bear cortical bone was broken into small fragments, 
defatted with a mixture of 3 parts hexane and 2 parts isopro-
panol, and lyophilized. The dried bone was ground to a fine 
powder under liquid nitrogen, and the osteocalcin was solu-
bilized as described by Hauschka et al. (1989, Physiol. Rev., 
69, 990-1047). Osteocalcin was purified from the resulting 
EDTA extract by a modification of the method of Colombo et 
al. (1993, J. Bone Miner. Res., 8, 733-43). Briefly, the crude 
EDTA solution was diluted 2-fold and passed over a bulk 
column containing 10 g Sepralyte C18 particles (Analyt-
ichem International, Harbor City, Calif.) previously activated 
with methanol and equilibrated with 0.1 % trifluoroacetic acid 
in water (0.1 % TFA).An extensive wash with 0.1% TFA was 
followed by 30% methanol/0.1% TFA until UV absorbance 
dropped to baseline. Osteocalcin was eluted with 80% metha-
nol/0.1 % TFA. Methanol was evaporated under a stream of 
air and the remaining solution lyophilized. The resulting 
dried protein was suspended in 0.05 M Tris buffer, pH 8.0 and 
applied to a 5 ml Biorad Econo-Q colunm previously equili-
brated with the same buffer. The colunm was developed with 
a gradient from 0.1 to 0.6 M NaCl in 0.5 M Tris, pH 8.0. 
Osteocalcin eluted in a symmetric peak, the last to elute from 
the colunm. Identity of this peak as osteocalcin was qualita-
tively verified by reacting fraction aliquots with diazoben-
zene sulfonic acid yielding a pink color in those fractions 
containing osteocalcin, with intensity corresponding to peak 
height. Both the Cl 8 and the Econo-Q column were new and 
Various primer combinations were used for PCR-based 
cloning of PTH from black bear genomic DNA. Based on the 
sequencing results of preliminary clones, a gene-specific 30 
sense primer corresponding to the start codon was designed 
and used along with a degenerate antisense primer containing 
the stop codon to amplify the entire coding region of PTH. A 
second antisense primer covering the stop codon was 
designed to generate a clone for sequence confirmation. 35 never exposed to protein from other species. Previous expe-
rience with other species suggests the final osteocalcin peak is 
greater than 99% pure. Concentration of black bear osteocal-
cin in the final elute was determined with BCA reagents from 
Sequence assembly revealed a precursor PTH protein of 
115 amino acids, including a 25 amino acid signal peptide and 
a 6 amino acid propeptide. The deduced mature protein is 84 
amino acids, with a calculated molecular weight of 9,471 
Daltons and a pl of 8.1. Black bear PTH shares 84-95% 40 
sequence similarity with other mammalian PTHs, and is most 
similar to dog PTH (91 % identity, 95% similarity) (FIG. 5). 
Interestingly, two amino acid residues, 41 and 52 of the 
mature hormone, are unique to black bear PTH. 
Example 2 
Levels of Bone Resorption and Formation Markers 
During Hibernation 
Serum Samples 
Blood samples were collected from five black bears (Ursus 
americanus) held in a captive bear research facility. The Vir-
ginia Polytechnic Institute and State University Animal Care 
Committee approved all bear handling protocols (#98-069-
F&WS). The bears were anesthetized with a 2:1 mixture of 
ketamine (100 mg/ml):xylazine (100 mg/ml); the dosage was 
1 cc of the mixture per 45.5 kg of body weight. Body tem-
peratures were 4' to 6° C. cooler during winter collection, 
confirming that the bears were in a state of hibernation. No 
urine or scat was present in the hibernation dens. Stressful 
behavior was not observed during any of the handling proce-
dures. Blood samples were drawn from the femoral vein 
while the bears were anesthetized, and the samples were 
transported to the laboratory in an ice-packed cooler. Imme-
diately on return to the laboratory, the blood was centrifuged 
to isolate the serum, which was frozen at -20° F. Blood 
Pierce Chemical (Rockford, Ill.). 
Biochemical Assays 
The serum was assayed for PTH, 25-OH D, leptin, IGF-I, 
and osteocalcin (a bone formation marker) using RIA and 
ELISA. 
Highly purified black bear osteocalcin and black bear 
45 serum were assayed by radioimmunoassay. The antibody was 
guinea-pig anti-rat osteocalcin and tracer was 1251-labeled rat 
osteocalcin. Dose dilutions of both rat osteocalcin standard 
(Biomedical Technologies, Inc, Stoughton, Mass.) and puri-
fied black bear osteocalcin were included in the assay. Ali-
50 quots of 10 µl black bear serum per assay tube were assayed 
in duplicate, and all samples were assayed at the same time. 
Duplicates varied by less than 5%. 
To observe changes in bone formation and resorption 
markers during disuse, the mean values of osteocalcin for the 
55 5 black bears were calculated for each time point during the 
hibernation period. These values were normalized by the 
maximum osteocalcin value during the hibernation period. 
Similar calculations were done for measurements of PICP 
(bone formation marker) and I CTP (bone resorption marker). 
60 The normalized values of the resorption and formation mark-
ers were plotted on the same graph to assess the temporal and 
relative magnitude changes in bone resorption and formation 
during disuse. 
Using serum samples from hibernating bears obtained as 
65 described above, ionized calcium concentration was mea-
sured with an ion-selective electrode (Bayer Rapidlab 865, 
Leverkusen, Germany). 
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Using serum samples obtained as described above, PTH 
was assayed with an ELISA kit from Immutopics Interna-
tional (San Clemente, Calif.); the intra-assay coefficient of 
variation was 4.7%. 25-OH D was assayed with an ELISA kit 
fromALPCO Diagnostics (Windham, N.H.); the intra-assay 5 
coefficient of variation was 5%. Leptin was measured by RIA 
(Linea, St. Charles, Mo.); the intra-assay coefficient of varia-
tion was 3.4%. IGF-I was measured by acid ethanol extrac-
tion RIA (Nichols Institute Diagnostics, San Juan Capistrano, 
Calif.); the intra-assay coefficient of variation was 4.3%. 
10 Serum osteocalcin was measured by RIA as described above. 
For all the serum metabolites, the mean values (for all bears 
and all time points within a given season) were calculated for 
each season (pre-hibernation, hibernation, and post hiberna-
tion) and compared by ANOVA. ANOVAs were followed up 
with Fisher's PLSD tests for multiple mean comparisons. 15 
Natural log transformations were used to correct non-con-
stancy of variance for osteocalcin, PTH, 25-OH D, and IGF-I 
14 
Example 3 
PGE2 Release by MC-3T3 Osteoblasts is Affected by 
Seasonal Variations in Bear Serum 
To assess the effects of seasonal variations in bear serum on 
osteoblast metabolism, MC-3T3 cells were treated with bear 
serum and prostaglandin E2 (PGE2 ) release was quantified. 
MC-3T3 cells were grown in alpha minimum essential media 
(Invitrogen, Carlsbad, Calif.) supplemented with 10% fetal 
bovine serum (Hyclone, Logan, Utah) and 1 % penicillin-
streptomycin solution at 37° C. in 5% CO2 for 24 hours. The 
media was aspirated and replaced with 10 ml of fresh media 
containing 10% bear serum collected prior to hibernation, 
during hibernation, or after hibernation. The cells were 
allowed to grow for an additional 24 hours, and then the 
media was collected and frozen at -20° C. for PGE2 analysis. 
The cells were removed from the culture dishes using 0.25% 
trypsin in EDTA, pelleted by centrifugation, and quantified 
to validate the ANOVAs. Linear regressions were used to 
assess the correlations between osteocalcin and the hor-
mones. The volume of some serum samples was insufficient 
to run all assays; sample sizes for each assay are indicated 
with the results. 
20 with a trypan blue and hemocytometer. 
Results 
The bone resorption marker (ICTP) began to increase 
immediately after the onset of hibernation (FIG. 3). Each data 
point is the mean value from 5 bears. After 10-20 days, the 
bone formation markers ( osteocalcin and PICP) also 
increased and appeared to remain coupled to the increased 
resorption for the duration of hibernation. This is consistent 
with the 1-2 week histological "reversal" period between 
resorption and formation. These remodeling markers showed 
trends of increased resorption and formation throughout the 
hibernation period, and formation appeared to remain 
coupled and balanced with resorption. Mean osteocalcin lev-
els were higher (p<0.0001) during and after hibernation com-
pared to pre-hibernation (Table 1 ). 
Hibernation ionized calcium levels were significantly 
(p=0.0062) higher than the pre-hibernation levels (Table 1). 
During remobilization following arousal from hibernation, 
ionized calcium levels did not significantly (p=0.37) increase 
relative to hibernation levels, but they remained higher 
(p=0.015) than pre-hibernation levels. 
Osteocalcin was positively correlated with PTH (FIG. 2), 
but not with 25-OH D, leptin, orIGF-I. PTH was significantly 
higher in the post-hibernation season than in the pre-hiberna-
tion (p=0.006) and hibernation (p=0.014) seasons. The 
increase in PTH during hibernation relative to pre-hiberna-
tion was not significant (p=0.35). 25-OH vitamin D did not 
show seasonal variations (p=0.64). 
The PGE2 levels were determined using the Biotrak™ 
PGE2 competitive enzyme immunoassay (Amersham Bio-
sciences, Piscataway, N.J.). The assay was performed in 
duplicate using 50 µl samples from all experimental media 
25 samples. The reaction was halted prior to endpoint determi-
nation using IM sulfuric acid and read at 450 nm using a 
microplate reader (VERSAmax, Molecular Devices Corpo-
ration, Sunnyvale, Calif.). The duplicate optical density val-
ues were corrected for nonspecific binding and were aver-
30 aged, and compared to a standard curve to determine the 
amount of PGE2 in each well. These values were corrected for 
total media volume and normalized by the number of cells in 
the sample. ANOVA was used to compare the normalized 
PGE2 between the three serum groups. 35 The amount of PGE2 , released by osteoblastic cells treated 
with bear serum in vitro, was higher for treatment with post-
hibernation serum compared to pre-hibernation serum 
(p=0.058) and hibernation serum (p=0.014) (FIG. 4). The 
PGE2 release for cells treated with the hibernation serum was 40 not significantly (p=0.48) different compared to the pre-hi-
bernation serum. The seasonal changes in PGE2 release 
showed trends similar to the seasonal changes in serum IGF-I. 
P-values are for comparisons with the post-hibernation value. 
Pre-hibernation and hibernation values were not different 
45 from each other (p=0.48). 
Example 4 
Serum leptin did not change during hibernation relative to 
pre-hibernation, but was significantly (p<0.004) lower during 
post-hibernation remobilization (Table 1). IGF-1 signifi- 50 
cantly (p<0.0001) decreased during hibernation relative to 
pre-hibernation and reached its highest value during remobi-
lization (Table 1). 
Culture in Bear Serum Decreases the Ratio of Gene 
Expression of Bax to Bcl-2 During Hibernation 
Blood serum samples were removed from 4 female black 
bears between 2004-2005 as described above. Sample dates 
TABLE 1 
Mean Serum Metabolite Concentrations 
Pre-hibernation Hibernation Post-hibernation 
Osteocalcin (ng/ml) 16.9a (7.4) [15] 70.4b (43.1) [22] 49.3b (26.8) [19] 
Ionized calcium (mmol/L) 0.709a (.150) [12] 0.871b (.093) [10] 0.960b (.014) [2] 
PTH (pg/ml) 14.6a (4.5) [6] 25.3a (27.3) [14] 41.4b (20.2) [9] 
25-OH D (nmol/ml) 16.6 (16.3) [9] 11.2 (6.2) [9] 16.0 (13.4) [9] 
Leptin (ng/ml) 4.oa (0.7) [15] 3.sa (0.7) [22] 3.lb (0.7) [19] 
IGF-1 (ng/ml) 3g7a (88) [15] 209b (52) [22] 594c (207) [19] 
Mean values are given in bold, standard deviations in parentheses, and sample sizes in brackets. For a given metabolite, values with the same superscript 
are not significantly (p < 0.05) different. 25-0H D did not show significant seasonal differences. 
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encompassed a pre-hibernation active period, a hibernation 
disuse period, and a post-hibernation remobilization period. 
MC-3T3 osteoblastic cells were cultured for 24 hours in 
media containing 10% bear serum, after which total RNA was 
isolated using a BioRadAquaPure RNA Isolation Kit (#732- 5 
6370, Bio-Rad Laboratories, Hercules, Calif.). To generate 
cDNA, reverse transcription was performed using Super-
script II reverse transcriptase (Invitrogen, Carlsbad, Calif.), 
and 0.5 µg Oligo(dT) 12-18 primer at 42° C. for 20 minutes, 
50° C. for 10 minutes and 42° C. for 1 hour in a gradient 10 
thermocycler (Mastercycler gradient, Eppendorf, Westbury, 
N.Y.). Primers for the pro-apoptotic protein Bax and the anti-
apoptotic protein Bcl-2 were designed using PrimerQuest 
software (Integrated DNA Technologies, Coralville, Iowa) 15 
and the NCBI gene bank sequences. Semi-quantitative PCR 
was performed using RedTaq and a protocol consisting of 94 ° 
C. for 2 minutes, cycles of94° C. for 30 seconds, 69.5° C. for 
30 sec and 72° C. for 1 minute, and a final extension at 72° C. 
for 5 minutes. Band intensity was quantified using the ImageJ 20 
software package (National Institutes of Health, Bethesda, 
Md.) and normalized to the expression of three housekeeping 
genes (Gapdh, ~-actin, cyclophillin). 
ANOVA with Fisher's Protected Least Significant Differ-
ence (PLSD) post-hoc test was used to compare the ratio of 25 
Bax to Bcl-2 for the three seasons (pre-hibernation, hiberna-
tion, post-hibernation). Though it did not achieve statistical 
significance (p=0.300), the Bax/Bcl-2 ratio decreased by 
approximately 42% during hibernation relative to pre-hiber-
nation. The lack of statistical significance was likely related to 30 
the small sample size (n=2 for each season). These data sug-
gest that serum from hibernating bears contains a biological 
molecule that decreases osteoblast apoptosis. Since endog-
enous PTH and the bone formation marker osteocalcin both 
increase during hibernation (Donahue et al., 2006; J. Exp. 35 
Biol., 209, 1630-8), it is possible that endogenous bear PTH 
causes a decrease in osteoblast apoptosis during hibernation, 
which in turn increases bone formation. 
Example 5 
Comparison of Effects of Black Bear vs. Human 
PTH 1-84 or Subfragments Thereof on cAMP in 
Bone Cell Lines 
40 
16 
concentrations in 1 mM acetic acid, and diluted to 10 uM 
working stock concentrations before use. 
Cell Culture 
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLO-
Y4 cells (obtained from L. F. Bonewald, University of Mis-
souri, Kansas City, Mo.) are maintained in alpha-minimum 
essential media, 1 % penicillin/streptomycin, and 10% serum 
(MC-3T3: 10%fetal bovine serum(FBS), MLO-Y4: 5% FBS 
and 5% bovine calf serum), at 37° C. in 5% CO2 . All proce-
dures described herein are repeated with independent cell 
cultures such that n=6 for all treatment combinations in each 
assay. 
Effects of PTH Treatment on Intracellular cAMP Activity 
MC-3 T3 and MLO-Y 4 cells are seeded at appropriate den-
sities (MC-3T3: 50,000 cells/cm2 , MLO-Y4 15,000 cells/ 
cm2) in 6-well plates. Cells are cultured overnight to reach 
optimal confluence. The culture media is then aspirated and 
replaced with media containing either 10% serum+vehicle (1 
mM acetic acid) or 10% serum+ 100 nM PTH (human or bear 
1-84, or a sub fragment thereof. Cells are cultured under these 
conditions for 10 or 30 minutes (Carter, P.H. et al., 1999, J. 
Biol. Chem. 274 (45), 31955-60; Chen, X. eta!., 2002,Am. J. 
Physiol. Cell Physiol. 283 (5), C1432-40; Schiller, P. C. et al., 
1999, J. Bone Miner. Res. 14 (9), 1504-12). Following cul-
ture, the cells are trypsinized, centrifuged, and resuspended in 
lysis buffer. The suspension is incubated for 10 minutes and 
centrifuged to separate cellular debris. The supernatant from 
the cell lysate (following a 2-fold dilution) is assayed for 
cAMP concentration using a competitive binding assay (Cy-
clic AMP Assay #KGE002, R&D Systems, Minneapolis, 
Minn.). 
With each of the polypeptides tested, there is an increase in 
cellular cAMP levels in response to the black bear PTH-based 
polypeptide. 
Example 6 
Comparison of Effects of Black Bear vs. Human 
PTH 1-84 or Sub fragments Thereof on Apoptosis in 
Bone Cell Lines 
Full-length recombinant black bear PTH (residues 1-84) is 
produced and its effects on apoptosis in bone cell lines (MC-
3 T3 osteoblastic cells and MLO-Y4 osteocytic cells) are 
Full-length recombinant black bear PTH (residues 1-84) is 
produced and its effects on levels of cyclic adenosine mono-
phosphate ( cAMP) concentration in bone cell lines (MC-3 T3 
osteoblastic cells and MLO-Y4 osteocytic cells) are investi-
gated and compared to results obtained using recombinant 
human PTH 1-84. Equivalent experiments are conducted 
using subfragments of black bear and human PTH, the sub-
fragments including amino acid residues 1-34, 1-36, 7-84, 
11-84, and41-52 of the full-length (1-84) mature protein. For 
some experiments, black bear and human PTH polypeptides 
are synthesized with solid-phase methods. 
45 investigated and are compared to results obtained using 
recombinant human PTH 1-84. Equivalent experiments are 
conducted using sub fragments ofblack bear and human PTH, 
the subfragments including amino acid residues 1-34, 1-36, 
7-84, 11-84, and 41-52 of the full-length (1-84) mature pro-
To determine the effect of various forms of recombinant 
black bear and human PTH polypeptides on cAMP levels in 
bone-forming cells, the cultured bone cells (MC-3T3 and 
MLO-Y4) are contacted for 10 or 30 minutes with human or 
black bear PTH full-length (i.e. amino acid residues 1-84) 
polypeptide or one of the above-listed subfragments. After 
the cell is contacted with the PTH polypeptide, cAMP con-
centration in the cell is measured using a competitive binding 
assay as described further below. 
For all of the experiments using recombinant polypeptides, 
the lyophilized peptides are reconstituted to 100 uM stock 
50 tein. For some experiments, black bear and human PTH 
polypeptides are synthesized with solid-phase methods. 
To determine the relative ability of black bear and human 
PTH to prevent osteoblast and osteocyte apoptosis (under 
pro-apoptotic conditions), cells are incubated with human or 
55 black bear PTH 1-84, or one of the subfragments listed above, 
for one hour. Afterwards, cells are treated for 6 hours with 
dexamethasone to induce apoptosis. Apoptosis is quantified 
with an ELISA, as described further below. 
For all of the experiments using recombinant polypeptides, 
60 the lyophilized peptides are reconstituted to 100 uM stock 
concentrations in 1 mM acetic acid, and diluted to 10 uM 
working stock concentrations before use. 
Additional experiments are performed with MC-3T3 cells 
using either 0.1 % or 10% FBS. Additional experiments with 
65 less (0.1 %) than the normal (10%) amountofFBS are run and 
the results are analyzed to determine whether there is a sig-
nificantly different response between experiments that are 
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(1-84) mature protein. For some experiments, black bear and 
human PTH polypeptides are synthesized with solid-phase 
methods. 
To determine the effect of black bear and human PTH on 
run with normal or lower levels of serum. In the experiments 
reported in this Example, the results are not affected by the 
amount of FBS that is used. Apoptosis protection studies 
show that each of the polypeptides tested reduces or prevents 
apoptosis in MC-3T3 cells. 
Cell Culture 
5 regulation of bone matrix, transcriptional regulatory, anti-
apoptosis (Bcl-2) genes, and the pro-apoptosis gene Bax, 
cells are cultured for 1 or 3 hours with human or bear PTH 
1-84 or a subfragment. Gene expression is quantified with 
real-time PCR. 
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLO-
Y4 cells (obtained from L. F. Bonewald, University of Mis-
souri, Kansas City, Mo.) are maintained in alpha-minimum 
essential media, 1 % penicillin/streptomycin, and 10% serum 10 
(MC-3T3: 10%fetal bovine serum(FBS), MLO-Y4: 5%FBS 
and 5% bovine calf serum), at 37° C. in 5% CO2 . All proce-
dures described herein are repeated with independent cell 
cultures such that n=6 for all treatment combinations in each 15 
assay. 
Effects of PTH Treatment on Apoptosis 
For all of the experiments using recombinant polypeptides, 
the lyophilized peptides are reconstituted to 100 uM stock 
concentrations in 1 mM acetic acid, and diluted to 10 uM 
working stock concentrations before use. 
Additional experiments are performed with MC-3T3 cells 
using either 0.1 % or 10% FBS. Additional experiments with 
less (0.1 %)than the normal (10%) amountofFBS are run and 
the results are analyzed to determine whether there is a sig-
nificantly different response between experiments that are 
run with normal or lower levels of serum. In the experiments 
reported in this Example, the results are not affected by the 
20 
amount ofFBS that is used. Real-time PCR is used to assess 
MC-3T3 cells are seeded at 50,000 cells/cm2 , and MLO-
Y4 cells are seeded at 15,000 cells/cm2 in 6-well plates and 
cultured overnight to reach optimal confluence. The culture 
media is aspirated and replaced with media containing either 
10% serum+vehicle (1 mM acetic acid) or 10% serum+l00 
nM PTH (human or bear 1-84, or a subfragment thereof). 
After a one-hour incubation (Jilka et al., 1999; J. Clin. Invest., 
104, 439-46), 10 µM dexamethasone or its vehicle (DMSO) is 25 
added to each well and cells are incubated for 6 hours (Bel-
lido, T. eta!., 2003, J. Biol. Chem. 278(50), 50259-72; Jilka et 
al., 1999, J. Clin. Invest., 104, 439-46). The PTH polypeptide 
gene expression levels at 1- and 3-hour time points following 
addition of the polypeptide, showing in particular that black 
bear PTH 1-34 upregulates gene expression in MC-3 T3 cells. 
Cell Culture 
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLO-
Y4 cells (obtained from L. F. Bonewald, University of Mis-
souri, Kansas City, Mo.) are maintained in alpha-minimum 
essential media, 1 % penicillin/streptomycin, and 10% serum 
(MC-3T3: 10%fetal bovine serum(FBS), MLO-Y4: 5% FBS 
and 5% bovine calf serum), at 37° C. in 5% CO2 . All proce-
dures described herein are repeated with independent cell 
cultures such that n=6 for all treatment combinations in each 
assay. 
Effects of PTH Treatment on Gene Expression 
or vehicle is left in situ during apoptosis induction because the 
suppression of apoptosis by PTH is self-limiting (Bellido et 30 
al., 2003). After 6 hours, cells are trypsinized, centrifuged, 
resuspended, and counted using a hemocytometer. 50,000 
cells are removed from the suspension and placed into lysis 
buffer. The lysate supernatant (following centrifugation) is 
removed for analysis and stored at -20° C. 35 MC-3T3 cells are seeded at a density of 50,000 cells/cm
2
, 
andMLO-Y4 cells are seeded at a densityof15,000 cells/cm2 
in 6-well plates and cultured overnight to reach optimal con-
fluence. The culture media are aspirated and replaced with 
media containing either 10% serum+vehicle (1 mM acetic 
Apoptosis is quantified from the lysate supernatant with an 
ELISA (Cell Death Detection ELISA, #1544675, Roche 
Applied Science, Indianapolis, Ind.). This assay detects 
mono- and oligonucleosomes from fragmented cellular DNA acid) or 10% serum+l00 nM PTH (human or bear 1-84, or a 
sub fragment as listed above). Cells are cultured under these 
conditions for 1 or 3 hours; these time points correspond with 
PTH-induced upregulation of c-fos and osteocalcin (Jiang et 
al., 2004, J. Biol. Chem., 279, 5329-37; Chen et al., 2002). 
Total RNA is isolated using the SV Total RNA Isolation 
System (Promega, Madison, Wis.). 
Reverse transcription to generate cDNA is performed 
using Superscript II reverse transcriptase (Invitrogen, Carls-
bad, Calif.), and 0.5 µg Oligo(dT) 12-18 primer at 42° C. for 
20 minutes, 50° C. for 10 minutes and 42° C. for 1 hour in a 
in the cytoplasmic fraction of cell lysates, and therefore pro- 40 
vides a good measure of the early and middle stages of apo-
ptosis. Briefly, samples are diluted in buffer solution and 
added to microplate wells coated with an anti-histone mouse 
monoclonal ( clone Hl 1-4) antibody. Lysate supernatant from 
the vehicle-treated cells serves as a negative control. Optical 45 
densities are measured at 405 nm following the addition of a 
peroxidase-conjugated anti-DNA mouse monoclonal (clone 
MCA-33) antibody, and the amount of apoptosis in each 
sample is determined relative to its corresponding negative 
control. All samples are assayed in duplicate. 50 gradient thermocycler (Mastercycler gradient, Eppendorf, 
Westbury, N.Y.). Primers for all genes ofinterest ( osteocalcin, 
osteopontin, type I collagen, c-fos, Runx2, Bax, Bcl-2, 
SOST) and housekeeping genes (Gapdh, ~-actin, cyclophil-
lin) are designed using PrimerQuest software (Integrated 
Each of the polypeptides tested decreased apoptosis of the 
cells (under pro-apoptotic conditions). 
Example 7 
Comparison of Effects of Black Bear vs. Human 
PTH 1-84 or Subfragments Thereof on Gene 
Expression in Bone Cell Lines 
Full-length recombinant black bear PTH (residues 1-84) is 
produced and its effects on levels of gene expression in bone 
cell lines (MC-3T3 osteoblastic cells and MLO-Y4 osteo-
cytic cells) are investigated and are compared to results 
obtained using recombinant human PTH 1-84. Equivalent 
experiments are conducted using subfragments of black bear 
and human PTH, the subfragments including amino acid 
residues 1-34, 1-36, 7-84, ll-84,and41-52ofthefull-length 
55 DNA Technologies, Coralville, Iowa) and the NCBI gene 
bank sequences, and the PCR conditions are optimized using 
RNA from MC-3T3 and MLO-Y4 cells. Real-time PCR is 
performed using the Mx3000P real-time PCR system (Strat-
agene, La Jolla, Calif.). The protocol involves a hot start at 
95° C. for 10 minutes followed by 40 cycles of 95° C. for 30 
60 seconds (denaturation), 69° C. for 1 minute (annealing) and 
72° C. for 1 minute ( extension). The exception to this protocol 
is for c-fos, which has an annealing temperature of 66° C. 
Each 25 µl reaction contains lx Absolute™ qPCR SYBR® 
green mix (ABgene, Rochester, N.Y.), 0.1 µM forward and 
65 reverse primer, and 2.5 ng total RNA equivalent cDNA tem-
plate. Gene expression is determined using the relative stan-
dard curve method normalized to the geometric mean of the 
US 7,994,129 B2 
19 
three housekeeping genes. All samples are measured in dupli-
cate, and any samples with a coefficient of variation (CV) 
greater than 10% are reanalyzed. 
The polypeptides cause an upregulation of bone matrix, 
transcriptional regulatory, and transcriptional activator genes, 5 
and a decrease in the expression ratio ofBax/Bcl-2. 
Example 8 
Comparison of the Effects of Black Bear Serum 
from Different Seasons on Bone Cell Apoptosis and 
Gene Expression, and Correlation with Serum Levels 
of PTH and Osteocalcin 
10 
20 
enous serum PTH concentrations are inversely related to apo-
ptosis levels, in that higher serum PTH levels correspond to 
lower rates of apoptosis, i.e. serum PTH concentrations are 
negatively correlated with apoptosis levels. 
Example 9 
In Vivo Testing of Bear PTH 
Black bear PTH, either full-length (1-84) or one of several 
functional subfragments thereof (1-34; 1-36; 7-84; 11-84; 
41-52), are tested in vivo for anabolic stimulation of bone 
cells compared to an equivalent human PTH or sub fragment. 
Each of the PTH polypeptides is synthesized and suspended 
in a pharmaceutically-appropriate carrier for subcutaneous 
injection. Full-length PTH or a functional fragment thereof, 
from either black bear or human, is administered to mice at a 
dose of 40 µg/kg body weight daily for 7 weeks. Black bear 
PTH or a functional fragments thereof cause greater increases 
20 in bone strength, mass, and mineral content than the equiva-lent human PTH polypeptide. 
Blood samples are collected from at least 3 different female 15 
black bears (Ursus americanus pallas) held in the Virginia 
Tech Center for Bear Research between 2004 and 2005. 
Serum from additional black bears is collected in subsequent 
years. The Virginia Polytechnic Institute and State University 
Animal Care Committee approved all bear handling proto-
cols (#98-069-F&WS). The bears are anesthetized with a 2: 1 
mixture ofketamine (l00·mg/ml):xylazine (lO0·mg/ml); the 
dosage is 1 cc of the mixture per45.5 kg of body mass. Blood 
samples are drawn from the femoral vein while the bears are 
anesthetized, and the samples are transported to the labora-
tory in an ice-packed cooler. Immediately on return to the 25 
laboratory, the blood is centrifuged to isolate the serum, 
which is then frozen at -20° C. Blood samples are collected 
from each bear every 10 days from the beginning of October 
until the end of May. Hibernation begins in early January and 
ends in early April. Thus, the collection dates encompass an 30 
active pre-hibernation period, a disuse hibernation period, 
and an active post-hibernation remobilization period. 
Aliquots of 10 µl of bear serum are assayed in duplicate for 
osteocalcin concentration by radioimmunoassay (Patterson-
Allen et al., 1982; Anal. Biochem., 120, 1-7). This assay has 35 
previously been validated for bears (Donahue et al., 2006; J. 
Exp. Biol., 209, 1630-8). The antibody is guinea-pig anti-rat 
osteocalcin and tracer is 125I-labeled rat osteocalcin. Aliquots 
of 100 µl of bear serum are assayed in duplicate for PTH 
concentration (Donahue et al., 2006; J. Exp. Biol., 209, 1630-
8) with an ELISA (Porcine Intact PTH ELISA Kit, #60-3305, 40 
Immutopics, Inc., San Clemente, Calif.). This assay binds the 
39-84 region of PTH, and requires the 13-34 region of PTH to 
calorimetrically report PTH concentration. Thus, it provides 
a good measure of intact (1-84) PTH concentration as well as 
C-terminal subfragments 7-84 and 11-84. This ELISA has 45 
been shown to cross-react with bear PTH (Donahue et al., 
2006; J. Exp. Biol., 209, 1630-8), and has 100% cross-reac-
tivity with human PTH. To validate this assay for black bears, 
samples of culture media containing 10 nM recombinant 
black bear or human PTH 1-84 are assayed in duplicate. The 50 
known concentration of the PTH samples is compared to the 
measured concentration determined from the assay's stan-
dard curve. Any potential difference in cross-reactivity deter-
mined from these samples is used as a correction for endog-
enous black bear PTH concentration in the black bear serum 55 
samples. 
The procedures described above for recombinant black 
bear PTH apoptosis and gene expression cell culture experi-
ments with cultured bone-type cells are repeated, substituting 
the 100 nM recombinant PTH-containing media with culture 
media containing 10% black bear serum (from pre-hiberna- 60 
tion, hibernation, or post-hibernation periods). The serum 
volumes are calculated following the PTH ELISA described 
above. 
Serum from the hibernation and post-hibernation seasons 
causes a greater prevention of apoptosis compared to pre- 65 
hibernation serum, because PTH is higher during hibernation 
and post-hibernation than in pre-hibernation serum. Endog-
Example 10 
Use of Bear PTH as Prophylactic Agent to Reduce or 
Prevent Bone Loss 
Osteoporosis is induced in mice by hindlimb suspension ( a 
disuse model of osteoporosis) and by ovariectomy (a post-
menopausal model of osteoporosis). After the hindlimb sus-
pension begins or the ovariectomy is completed, the mouse is 
given regular doses of black bear PTH or a functional frag-
ment thereof. The mice treated with black bear PTH or func-
tional fragments thereof show less bone loss than untreated 
mice. 
Example 11 
Bear and Human PTH 1-34 Both Upregulate Gene 
Expression ofOsteocalcin, but Only Bear PTH 1-34 
Decreases the Expression Ratio ofBax/Bcl-2 
MC-3T3 cells were incubated in vehicle or 100 nM syn-
thetic bear or human PTH 1-34 for 3 or 6 hours (n=2 or 4). 
Total RNA was isolated, and cDNA was generated with 
reverse transcription. Primers for the bone matrix proteins 
type I collagen and osteocalcin, the pro-apoptotic protein 
Bax, the anti-apoptotic protein Bcl-2, and the housekeeping 
genes Gapdh, ~-actin, and cyclophillin were designed using 
PrimerQuest software (Integrated DNA Technologies, Cor-
alville, Iowa). Real-time PCR was performed using the 
Mx3000P real-time PCR system (Strata gene, LaJolla, Calif.). 
All samples were measured in duplicate. Gene expression 
was determined using the relative standard curve method 
normalized to the geometric mean of the three housekeeping 
genes (Gapdh, ~-actin, and cyclophillin). Apoptosis-related 
genes were analyzed as the expression ratio of Bax/Bcl-2, 
since a decrease in this ratio is associated with decreased 
apoptosis in vitro. 
Culture in human or bear PTH 1-34 for 6 hours did not 
affect expression of type I collagen but substantially upregu-
lated the expression of osteocalcin compared to the vehicle 
control (FIG. 6). There were no significant differences 
between human and bear PTH (p>0.09). 
Culture in bear PTH 1-34 for 3 hours decreased the expres-
sion ratio ofBax/Bcl-2, suggesting decreased apoptosis, but 
culture in human PTH 1-34 for 3 hours increased the ratio, 
suggesting increased apoptosis (FIG. 7). The difference 
between bear and human PTH was statistically significant 
(p=0.047). 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 13 
<210> SEQ ID NO 1 
<211> LENGTH, 255 
<212> TYPE, DNA 
<213> ORGANISM, Ursus americanus 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) .. (252) 
<223> OTHER INFORMATION, cDNA encoding mature PTH polypeptide 
<400> SEQUENCE, 1 
tct gtg age gag ata cag ttt atg cat aac ctg ggc aaa cat ctg age 48 
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser 
1 5 10 15 
tee atg gag agg gtg gaa tgg ctg egg aag aag ctg cag gac gtg cac 96 
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
aac ttt gtt gee ctt gga get cca aca gcg cac aga gat ggt ggt tee 144 
Asn Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser 
35 40 45 
cag agg CCC cag aaa aag gaa gac aat gtg ctg gtt gag aac cat caa 192 
Gln Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln 
50 55 60 
aaa agt etc gga gaa gca gac aaa get gat gtg gat gta tta ace aaa 240 
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys 
65 70 75 80 
tct aaa CCC caa tga 255 
Ser Lys Pro Gln 
<210> SEQ ID NO 2 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM, Ursus americanus 
<400> SEQUENCE, 2 
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser 
1 5 10 15 
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser 
35 40 45 
Gln Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln 
50 55 60 
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys 
65 70 75 80 
Ser Lys Pro Gln 
<210> SEQ ID NO 3 
<211> LENGTH, 348 
<212> TYPE, DNA 
<213> ORGANISM, Ursus americanus 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) .. (345) 
<223> OTHER INFORMATION, cDNA encoding full-length PTH polypeptide 
<400> SEQUENCE, 3 
atg atg tct gcg aaa aac gtg gtt aaa gta atg att gtc atg ttt gca 48 
Met Met Ser Ala Lys Asn Val Val Lys Val Met Ile Val Met Phe Ala 
1 5 10 15 
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att tgt ttt ctt gca aaa tcg gat ggg aaa cct gtt aag aag aga tct 96 
Ile Cys Phe Leu Ala Lys Ser Asp Gly Lys Pro Val Lys Lys Arg Ser 
20 25 30 
gtg age gag ata cag ttt atg cat aac ctg ggc aaa cat ctg age tee 144 
Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser 
35 40 45 
atg gag agg gtg gaa tgg ctg egg aag aag ctg cag gac gtg cac aac 192 
Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn 
50 55 60 
ttt gtt gee ctt gga get cca aca gcg cac aga gat ggt ggt tee cag 240 
Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser Gln 
65 70 75 80 
agg CCC cag aaa aag gaa gac aat gtg ctg gtt gag aac cat caa aaa 288 
Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln Lys 
85 90 95 
agt etc gga gaa gca gac aaa get gat gtg gat gta tta ace aaa tct 336 
Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ser 
100 105 110 
aaa CCC caa tga 348 
Lys Pro Gln 
115 
<210> SEQ ID NO 4 
<211> LENGTH, 115 
<212> TYPE, PRT 
<213> ORGANISM, Ursus americanus 
<400> SEQUENCE, 4 
Met Met Ser Ala Lys Asn Val Val Lys Val Met Ile Val Met Phe Ala 
1 5 10 15 
Ile Cys Phe Leu Ala Lys Ser Asp Gly Lys Pro Val Lys Lys Arg Ser 
20 25 30 
Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser 
35 40 45 
Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn 
50 55 60 
Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser Gln 
65 70 75 80 
Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln Lys 
85 90 95 
Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ser 
100 105 110 
Lys Pro Gln 
115 
<210> SEQ ID NO 5 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM, Macaca fascicularis 
<400> SEQUENCE, 5 
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1 5 10 15 
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Ile Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser 
35 40 45 
Gln Arg Pro Arg Lys Lys Glu Asp Asn Ile Leu Val Glu Ser His Glu 
50 55 60 
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Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys 
65 70 75 80 
Ala Lys Ser Gln 
<210> SEQ ID NO 6 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 6 
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1 5 10 15 
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser 
35 40 45 
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu 
50 55 60 
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys 
65 70 75 80 
Ala Lys Ser Gln 
<210> SEQ ID NO 7 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM, Equus caballus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (65) .. (65) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 7 
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1 5 10 15 
Ser Val Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Ile Ala Leu Gly Ala Pro Ile Phe His Arg Asp Gly Gly Ser 
35 40 45 
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Ile Glu Ser His Gln 
50 55 60 
Xaa Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ser Lys 
65 70 75 80 
Thr Lys Ser Gln 
<210> SEQ ID NO 8 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM: Canis lupus familiaris 
<400> SEQUENCE, 8 
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser 
1 5 10 15 
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Val Ala Leu Gly Ala Pro Ile Ala His Arg Asp Gly Ser Ser 
35 40 45 
Gln Arg Pro Leu Lys Lys Glu Asp Asn Val Leu Val Glu Ser Tyr Gln 
50 55 60 
26 
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Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys 
65 70 75 80 
Ala Lys Ser Gln 
<210> SEQ ID NO 9 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM, Felis catus 
<400> SEQUENCE, 9 
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser 
1 5 10 15 
Ser Val Glu Arg Val Glu Trp Leu Arg Arg Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Val Ala Leu Gly Ala Pro Ile Ala His Arg Asp Gly Gly Ser 
35 40 45 
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Pro Ala Glu Asn His Gln 
50 55 60 
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile Lys 
65 70 75 80 
Ala Lys Ser Gln 
<210> SEQ ID NO 10 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM, Bos taurus 
<400> SEQUENCE, 10 
Ala Val Ser Glu Ile Gln Phe Met 
1 5 
Ser Met Glu Arg Val Glu Trp Leu 
20 
His Asn Leu Gly Lys His Leu Ser 
10 15 
Arg Lys Lys Leu Gln Asp Val His 
25 30 
Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser Ser 
35 40 45 
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gln 
50 
Lys Ser Leu Gly Glu 
65 
Ala Lys Pro Gln 
<210> SEQ ID NO 11 
<211> LENGTH, 84 
<212> TYPE, PRT 
55 
Ala Asp 
70 
<213> ORGANISM, Sus scrofa 
<400> SEQUENCE, 11 
60 
Lys Ala Asp Val Asp Val Leu Ile Lys 
75 80 
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ser 
1 5 10 15 
Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Val Ala Leu Gly Ala Ser Ile Val His Arg Asp Gly Gly Ser 
35 40 45 
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gln 
50 55 60 
Lys Ser Leu Gly Glu Ala Asp Lys Ala Ala Val Asp Val Leu Ile Lys 
65 70 75 80 
Ala Lys Pro Gln 
28 
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<210> SEQ ID NO 12 
<211> LENGTH, 84 
<212> TYPE, PRT 
<213> ORGANISM: Rattus norvegicus 
<400> SEQUENCE, 12 
Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala 
1 5 10 15 
Ser Val Glu Arg Met Gln Trp Leu Arg Lys Lys Leu Gln Asp Val His 
20 25 30 
Asn Phe Val Ser Leu Gly Val Gln Met Ala Ala Arg Glu Gly Ser Tyr 
35 40 45 
Gln Arg Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Ser 
50 55 60 
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys 
65 
Ala Lys Ser Gln 
<210> SEQ ID NO 13 
<211> LENGTH, 84 
<212> TYPE, PRT 
70 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 13 
75 80 
Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala 
1 5 10 15 
Ser Met Glu Arg Met Gln Trp Leu Arg Arg Lys Leu Gln Asp Met His 
20 25 30 
Asn Phe Val Ser Leu Gly Val Gln Met Ala Ala Arg Asp Gly Ser His 
35 40 45 
Gln Lys Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Pro 
50 55 60 
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys 
65 70 75 80 
Ser Lys Ser Gln 
What is claimed is: 
1. A method of increasing cAMP levels in a bone-forming 
cell comprising contacting the bone-forming cell with an 
effective amount of a polypeptide comprising amino acid 
residues 1-34 of SEQ ID NO: 2, wherein contacting the 
bone-forming cell with the polypeptide increases cAMP lev-
els in the bone-forming cell, and wherein the bone-forming 
cell is in a human subject. 
2. The method of claim 1, wherein the polypeptide com-
prises amino acid residues 1-36 of SEQ ID NO:2. 
3. The method of claim 1, wherein the polypeptide com-
prises SEQ ID NO: 2. 
4. A method ofreducing apoptosis in a bone-forming cell 
comprising contacting the bone-forming cell with an effec-
tive amount of a polypeptide comprising amino acid residues 
1-34 of SEQ ID NO: 2, wherein contacting the bone-forming 
cell with the polypeptide reduces apoptosis in the bone-form-
ing cell, and wherein the bone-forming cell is in a human 
subject. 
5. The method of claim 4, wherein the polypeptide com-
prises amino acid residues 1-36 of SEQ ID NO: 2. 
6. The method of claim 4, wherein the polypeptide com-
prises SEQ ID NO: 2. 
7. A method of decreasing the ratio of expression levels of 
Bax protein to Bcl-2 protein in a bone-forming cell compris-
ing contacting the bone-forming cell with an effective amount 
45 of a polypeptide comprising amino acid residues 1-34 of SEQ 
ID NO: 2, wherein contacting the bone-forming cell with the 
polypeptide decreases the ratio of expression levels of Bax 
protein to Bcl-2 protein in the bone-forming cell, and wherein 
the bone-forming cell is in a human subject. 
50 8. The method of claim 7, wherein the polypeptide com-
prises amino acid residues 1-36 of SEQ ID NO: 2. 
9. The method of claim 7, wherein the polypeptide com-
prises SEQ ID NO: 2. 
10. A method of increasing the expression level of one or 
55 more of a bone matrix protein, a transcriptional activator, or a 
transcriptional regulator in a bone-forming cell comprising 
contacting the bone-forming cell with an effective amount of 
a polypeptide comprising amino acid residues 1-34 of SEQ 
ID NO: 2, wherein contacting the bone-forming cell with the 
60 polypeptide increases the expression level of the bone matrix 
protein, the transcriptional activator, or the transcriptional 
regulator in the bone-forming cell, and wherein the bone-
forming cell is in a human subject. 
11. The method of claim 10, wherein polypeptide com-
65 prises amino acid residues 1-36 of SEQ ID NO: 2. 
12. The method of claim 10, wherein the polypeptide com-
prises SEQ ID NO: 2. 
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16. The method of claim 13, wherein the polypeptide com-
prises amino acid residues 1-36 of SEQ ID NO: 2. 
17. The method of claim 13, wherein the polypeptide com-
prises SEQ ID NO: 2. 
18. A method of enhancing bone mineral density, increas-
ing bone mass, decreasing bone loss, or reducing the inci-
dence of bone fractures, or any combination thereof, in a 
human subject, comprising contacting a bone-forming cell in 
the human subject with an effective amount of a polypeptide 
13. A method of enhancing bone mineral density, increas-
ing bone mass, decreasing bone loss, or reducing the inci-
dence of bone fractures, or any combination thereof, in a 
human subject, comprising contacting a bone-forming cell in 
the human subject with an effective amount of a polypeptide 5 
comprising amino acid residues 1-34 of SEQ ID NO: 2, 
wherein contacting the bone-forming cell with the polypep-
tide enhances bone mineral density, increases bone mass, 
decreases bone loss, or reduces the incidence of bone frac-
tures in the human subject. 10 comprising bear parathyroid hormone or a functional frag-ment thereof, wherein contacting the bone-forming cell with 
the polypeptide enhances bone mineral density, increases 
bone mass, decreases bone loss, or reduces the incidence of 
bone fractures in the human subject. 
14. The method of claim 13, wherein the human subject is 
a post-menopausal female human afflicted with osteoporosis. 
15. The method of claim 13 further comprising adminis-
tering vitamin D and calcium to the human subject. * * * * * 
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